SI-BONE Names Jeryl (“Jeri”) Hilleman to Board of Directors

    NEXT STORY
    Adaptive Biotechnologies and Collaborators to Present Data from More Than 25 clonoSEQ® Abstracts at ASH 2019 Demonstrating Clinical Relevance of Standardized, Accurate MRD Testing for Blood Cancer Patients
    PREV STORY
    Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary Disease
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    BeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 Congress

    CAMBRIDGE, Mass. and BEIJING, China, Sept. 08, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), ...

    author_avatar
    NASDAQ Market News

    Oasmia Pharmaceutical AB (publ)

    author_avatar
    NASDAQ Market News

    Evogene Reports First Quarter 2018 Financial Results

    Conference call and webcast, today at 9:00 am Eastern TimeREHOVOT, Israel, May 29, 2018 ...

    author_avatar
    NASDAQ Market News